
Seelos Therapeutics SEEL
Quarterly report 2024-Q2
added 08-14-2024
Seelos Therapeutics P/CF Ratio 2011-2026 | SEEL
Annual P/CF Ratio Seelos Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.227 | -0.0639 | - | -4.85 | -1.13 | -0.412 | -2.75 | -1.17 | -2.4 | -2.96 | -5.04 | -4.92 | -9.98 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.0639 | -9.98 | -2.99 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-94.9 | $ 3.6 | 1.34 % | $ 8.66 B | ||
|
Aytu BioScience
AYTU
|
-8.14 | $ 2.66 | - | $ 16.7 M | ||
|
BioNTech SE
BNTX
|
70.7 | $ 91.28 | - | $ 27.2 B | ||
|
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B | ||
|
Burford Capital Limited
BUR
|
11.6 | $ 4.48 | - | $ 736 M | ||
|
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | ||
|
Cerus Corporation
CERS
|
102 | $ 1.85 | - | $ 353 M | ||
|
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | ||
|
Coherus BioSciences
CHRS
|
-1.63 | $ 1.67 | - | $ 196 M | ||
|
Celldex Therapeutics
CLDX
|
-9.67 | $ 31.37 | - | $ 2.08 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-2 | $ 0.44 | - | $ 5.04 M | ||
|
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | ||
|
CNS Pharmaceuticals
CNSP
|
-0.0767 | $ 2.32 | - | $ 1.03 M | ||
|
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - | ||
|
Catalyst Pharmaceuticals
CPRX
|
14.6 | $ 24.98 | - | $ 3.05 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-1.97 | $ 10.14 | - | $ 135 M | ||
|
Cardiff Oncology
CRDF
|
-3.07 | $ 1.58 | - | $ 106 M | ||
|
Curis
CRIS
|
-0.348 | $ 0.53 | - | $ 6.98 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-10.9 | $ 37.7 | - | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
-12.7 | $ 49.15 | - | $ 4.42 B | ||
|
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | ||
|
CytomX Therapeutics
CTMX
|
-12.3 | $ 4.4 | - | $ 607 M | ||
|
Citius Pharmaceuticals
CTXR
|
-0.859 | $ 0.86 | - | $ 5.79 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | ||
|
Cue Biopharma
CUE
|
-1.35 | $ 0.18 | - | $ 17.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | ||
|
DBV Technologies S.A.
DBVT
|
-23.3 | $ 20.36 | - | $ 2.84 B | ||
|
AIkido Pharma
AIKI
|
-1.17 | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
-0.0645 | - | -45.71 % | $ 1.2 M | ||
|
Denali Therapeutics
DNLI
|
-8.74 | $ 19.38 | - | $ 3.19 B | ||
|
Dyadic International
DYAI
|
-5.52 | $ 0.87 | -2.8 % | $ 31.5 M | ||
|
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-765 | $ 3.54 | - | $ 238 B | ||
|
Akouos
AKUS
|
-2.7 | - | 0.23 % | $ 488 M | ||
|
Entera Bio Ltd.
ENTX
|
-2.93 | $ 1.19 | - | $ 55.5 M | ||
|
Equillium
EQ
|
-5.19 | $ 2.01 | - | $ 115 M | ||
|
Allakos
ALLK
|
-0.976 | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
-2.48 | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
77.9 | $ 330.34 | - | $ 43.3 B | ||
|
Alpine Immune Sciences
ALPN
|
-6.14 | - | - | $ 2.17 B | ||
|
Fate Therapeutics
FATE
|
-1.76 | $ 1.19 | - | $ 141 M | ||
|
Aileron Therapeutics
ALRN
|
-1.71 | - | 10.36 % | $ 9.8 M |